D58

Climate transition risk in the banking sector: what can prudential regulation do?

Retrieved on: 
토요일, 2월 17, 2024
Working, RWE, Workshop, N2O, Climate, DD, Policy, CES, Macroeconomics, Research Papers in Economics, University, Deleveraging, A.6, PFC, A.7, AWI, Canadian International Council, FRB, Paper, RTF, NX, Household, Economy, Carbon, BTI, Central bank, Classification, Lit, Capital, UH, Government, Parameter, Q54, Credit, Social science, Constantine Dafermos, Simons Foundation, PD, LE, Investment, Part, A.4, AA, A.5, PB, Section 2, Probability, E61, Um, LCI, COVID-19, Coronavirus, Financial regulation, Equation, MCI, Control Engineering (magazine), Environment, CIT, Bank of England, GSF, Directorate, Shock, Relaxation, European Central Bank, DP, Abstract, PTI, DPF, Face, AWB, DSGE, Website, Calibration, Prudential, Ben Bernanke, Climate change, Macroprudential regulation, Money, CRRA, Bank, LH, Methodology, HCI, RF, D58, BK, European Commission, Risk, Biophysical environment, NF3, NCDF, CO2, Acquisition, JEL, Sustainability, American wire gauge, QT, Journal of Financial Stability, BCBS, CSS, Motion, ECB, HFC, RT, CTH, Exercise, Tax, European Parliament, Literature, Qi, Reproduction, LGD, KT, European Green Deal, SF6, Council, DT, FOC, Journal, LG, RSS, EPF, University of Poitiers, UI, ESG, CC, Internalization, CH4, PDF, DTH, RTÉ, Communications satellite
Key Points: 

    Novocure Announces Portfolio Prioritization and Strategic Restructuring Plan Focused on Near-term Growth Drivers and an Accelerated Path to Profitability

    Retrieved on: 
    화요일, 11월 28, 2023
    Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Lung cancer, Workforce, Investment, Growth, Cancer, Patient, D58, METIS, TRIDENT, Risk management, Pharmaceutical industry

    Novocure (NASDAQ: NVCR) today announced a series of actions to strengthen and optimize business operations to support near-term growth drivers and long-term value creation.

    Key Points: 
    • Novocure (NASDAQ: NVCR) today announced a series of actions to strengthen and optimize business operations to support near-term growth drivers and long-term value creation.
    • “Decisions like these are deeply personal and challenging, because of the impact on our employees and their families,” said Novocure’s Chief Executive Officer, Asaf Danziger.
    • In conjunction with its portfolio prioritization, Novocure is streamlining its operational expenses.
    • The anticipated cost savings are expected to offset growth investments and accelerate Novocure’s path to profitability.

    USDA APHIS seeks public comments on their evaluations of blight-tolerant American chestnut trees

    Retrieved on: 
    목요일, 12월 15, 2022
    Genetic engineering, Health, ESF, Environmental science, Tree, State University of New York at Purchase, Forestry, EIS, Safety, State College, Pennsylvania, News, Environmental issues, Biotechnology, Newhouse, USDA, PPRA, The American Chestnut Foundation, Environment, State University of New York College of Environmental Science and Forestry, Organization, Livestock, Research, Social media, TACF, Volunteering, Hunting, D58

    Once one of the largest tree species in the eastern forests of North America, the American chestnut could reach towering heights in the forest canopy.

    Key Points: 
    • Once one of the largest tree species in the eastern forests of North America, the American chestnut could reach towering heights in the forest canopy.
    • The American chestnut was devastated by a fungal blight discovered in the early 1900s, and the tree is now considered to be functionally extinct.
    • A team of researchers at ESF has been working in collaboration with TACF to produce a blight-tolerant American chestnut variety using genetic engineering.
    • “We’re pleased that regulatory review with Darling 58 is progressing, and optimistic about the future of American chestnut restoration,” says Newhouse.

    Novocure Reports Second Quarter 2022 Financial Results

    Retrieved on: 
    목요일, 7월 28, 2022
    Biotechnology, General Health, Health, Oncology, MSD, Private Securities Litigation Reform Act, Investment, Stomach, Trastuzumab, GBM, Data collection, Glioblastoma, Research, Twitter, Pembrolizumab, Trial of the century, Large-cell lung carcinoma, U.S. Securities and Exchange Commission, Disclosure, Forward-looking statement, Prescription, Pancreatic cancer, Alternating electric field therapy, Partnership, Mesothelioma, Marketing, Merck & Co., Adult, Safety, COVID-19, Regulation, EMEA, NASDAQ, D58, Cancer, Progression-free survival, EDT, GAAP, Adoption, Webcast, Merck, PD-L1, Liver cancer, NSCLC, FDA, Science, Patient, LinkedIn, Survival, Annual report, Regulation Fair Disclosure, Ovarian cancer, Neoplasm, Tax, Depreciation, EBITDA, Pharmaceutical industry, Lithium, Bookkeeping, Tutoring

    Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended June 30, 2022.

    Key Points: 
    • Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended June 30, 2022.
    • Financial updates for the second quarter ended June 30, 2022:
      Total net revenues for the quarter were $140.9 million, an increase of 6% compared to the same period in 2021.
    • Operational updates for the second quarter ended June 30, 2022:
      As of June 30, 2022, there were 3,454 active patients on therapy.
    • Novocure will host a conference call and webcast to discuss second quarter 2022 financial results at 8 a.m. EDT today, Thursday, July 28, 2022.